The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Effect of the combination of systemic and locoregional therapy on tumor recurrence and survival after liver transplantation for hepatocellular carcinoma (HCC).
 
Khadyoth Nanneboyina
No Relationships to Disclose
 
Ali Khurram
No Relationships to Disclose
 
Ashwini Mehta
No Relationships to Disclose
 
Judith Pozzerle
No Relationships to Disclose
 
Parvez Mantry
Consulting or Advisory Role - Abbvie; Amgen; Boston Scientific; Cymabay Therapeutics; Eisai; Gilead Sciences; Intercept Pharmaceuticals; Ipsen; Madrigal Pharmaceuticals; Mallinckrodt; Novo Nordisk; Salix; Sirtex Medical
Speakers' Bureau - Abbvie; Amgen; BMS GmbH & Co. KG; Boston Scientific; Eisai; Gilead Sciences; GORE; Intercept Pharmaceuticals; Ipsen; Madrigal Pharmaceuticals; Novo Nordisk; Salix; Sirtex Medical
Research Funding - Akero Therapeutics; Aldeyra Therapeutics; BMS GmbH & Co. KG; Care Dx; Chemomab Therapeutics; Cymabay Therapeutics; Fibronostics; Genentech; GENFIT; Gilead Sciences; GlaxoSmithKline; Hanmi; HepQuant; Intercept Pharmaceuticals; Inventiva Pharma; Lipocine; Madrigal Pharmaceuticals; Mirum Pharmaceuticals; Novo Nordisk; Regeneron; Salix; Sirtex Medical; Taiho Pharmaceutical; Tempest Therapeutics; TransThera Biosciences; Viking Medical